Your trusted source for investing success
Q BioMed Inc. (OTCQB:QBIO), is very pleased to announce their entry into a final license agreement with The Oklahoma Medical Research Foundation (OMRF) and the Rajiv Gandhi Centre for Biotechnology (RGCB). Under the agreement QBioMed has the global exclusive rights to develop and market a novel chemotherapeutic drug to treat
By Jocelyn Aspa
The basics you need to know about the tiny particles making a big impact on science.
Propanc Biopharma announced new insights about how cancer stem cells can resist standard treatments, become more aggressive and spread rapidly.
Keeping with his promise to change the FDA, Trump reveals an increase of user fees in the budget.
Who are the top performing ETFs in the pharmaceuticals, biotechnology and life sciences markets year-to-date?
NEW YORK, February 7, 2017 – Q BioMed Inc. (OTCQB:QBIO) has entered into an agreement with the Oklahoma Medical Research Foundation (OMRF) and the Rajiv Gandhi Centre for Biotechnology (RGCB) to develop a chemotherapeutic technology to treat liver cancer.
Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it is collaborating with the newly-established Food for Health Center at the University of Nebraska (“NU”) to study the role
Calico is just one company that promises to make major headlines in the longevity investing space.
Novartis announced today additional analyses from the Phase III MONALEESA-2 study that show LEE011 (ribociclib) plus letrozole significantly prolonged progression-free survival (PFS) across pre-planned patient subgroups.
MRI Interventions today announced financial results for the quarter and nine months ended September 30, 2016.
Spark Therapeutics announced today a multi-year research agreement with Guangping Gao, Ph.D., the Penelope Booth Rockwell Chair in Biomedical Research, director of the Horae Gene Therapy Center, and professor of microbiology and physiological systems at the University of Massachusetts Medical School.
Hansa Medical today announced that the firstpatient has been recruited and treated in a Phase II clinical study with IdeS in the acute autoimmune disease acquired Thrombotic Thrombocytopenic Purpura (TTP).
FenoLogica Biosciences Inc., a Seattle-WA-based life sciences company, announces completion of a licensing and collaboration agreement with the Pacific Northwest Research Institute (PNRI). FenoLogica also announces closing of its seed investment round that took place on June 13, 2016.
FenoLogica’s technology combines novel quantitative biology measurement techniques with cloud-based analytical tools
DALLAS, May 11, 2016 /PRNewswire-USNewswire/ — At one of the country’s leading academic medical centers, it just became a lot easier to take a closer look.
UT Southwestern Medical Center has announced the opening of a new $17 million cryo-electron microscope (cryo-EM) facilityhousing a unique collection of instruments that researchers can use
BELLEVUE, Wash.–(BUSINESS WIRE)–Translational Software®, Inc. (TSI), a leader in the intelligent use of genetic data for clinical decision support and precision medicine, today announced a 12-month pilot with Inova Translational Medicine Institute (ITMI), a research institute developing innovative methods for personalized healthcare. Use of TSI’s pharmacogenomics (PGx) knowledge base and
Medical care and biomedical research are being transformed by data collection. Pharmaceutical Processing outlines what this means for the pharmaceutical industry.
Whether biotech stocks keep up the scorching pace of 2013 remains to be seen, but we can count on one thing going forward, says Cantor Fitzgerald Senior Analyst Mara Goldstein. We are still in a catalyst-driven market. In this interview with The Life Sciences Report, Goldstein discusses four names with
By Vivien Diniz
Antibiotic-resistant bacteria, like the proverbial time bomb, are poised to wreak infectious havoc on a worldwide scale. Brad Spellberg, associate professor of medicine at the Los Angeles Biomedical Research Institute and the Harbor-UCLA Medical Center, is committed to defusing the bomb with the development of new antibiotics and creative
Forbes reported that legendary drug industry executives, Marc Tessier-Lavigne, P. Roy Vagelos, and Elias Zerhouni said even seemingly insignificant budget cuts on biomedical research and innovation could pose a danger to the future.
